Diagnosis and management of neonatal leukaemia

Marieke H. Van der Linden; Sara Creemers; Rob Pieters

doi:10.1016/j.siny.2012.03.003

Diagnosis and management of neonatal leukaemia

Marieke H. Van der Linden
, Sara Creemers
, Rob Pieters

Research output: Contribution to journal › Review article › peer-review

54 Citations (Scopus)

Abstract

Leukaemia in neonates (infants <1 month) is rare, whereby neonatal acute myeloid leukaemia (AML) is more frequent than neonatal acute lymphoblastic leukaemia (ALL). High mortality rates are observed, though AML has a better prognosis than ALL. Neonatal leukaemia is typically presented with hepatosplenomegaly, leukaemia cutis and/or hyperleucocytosis. Congenital infections should be ruled out before diagnosis. Rearrangement of the . MLL gene is the most frequently occurring genetic aberration. Treatment includes intensive multi-agent chemotherapy, usually with age-related dose adjustments next to supportive care. Treatment intensification for ALL could be indicated in the future as the dismal prognosis is subject to high relapse rates in ALL.

Original language	English
Pages (from-to)	192-195
Number of pages	4
Journal	Seminars in Fetal and Neonatal Medicine
Volume	17
Issue number	4
DOIs	https://doi.org/10.1016/j.siny.2012.03.003
Publication status	Published - Aug 2012
Externally published	Yes

Keywords

Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Mixed lineage leukaemia
Neonate

Access to Document

10.1016/j.siny.2012.03.003

Cite this

@article{243248b4b87d46bc89cfb456229a7e96,

title = "Diagnosis and management of neonatal leukaemia",

abstract = "Leukaemia in neonates (infants <1 month) is rare, whereby neonatal acute myeloid leukaemia (AML) is more frequent than neonatal acute lymphoblastic leukaemia (ALL). High mortality rates are observed, though AML has a better prognosis than ALL. Neonatal leukaemia is typically presented with hepatosplenomegaly, leukaemia cutis and/or hyperleucocytosis. Congenital infections should be ruled out before diagnosis. Rearrangement of the . MLL gene is the most frequently occurring genetic aberration. Treatment includes intensive multi-agent chemotherapy, usually with age-related dose adjustments next to supportive care. Treatment intensification for ALL could be indicated in the future as the dismal prognosis is subject to high relapse rates in ALL.",

keywords = "Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Mixed lineage leukaemia, Neonate",

author = "\{Van der Linden\}, \{Marieke H.\} and Sara Creemers and Rob Pieters",

note = "Funding Information: M.H.vdL. is supported by Kinderen Kankervrij (KiKa, project number 1713074).",

year = "2012",

month = aug,

doi = "10.1016/j.siny.2012.03.003",

language = "English",

volume = "17",

pages = "192--195",

journal = "Seminars in Fetal and Neonatal Medicine",

issn = "1744-165X",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Diagnosis and management of neonatal leukaemia

AU - Van der Linden, Marieke H.

AU - Creemers, Sara

AU - Pieters, Rob

N1 - Funding Information: M.H.vdL. is supported by Kinderen Kankervrij (KiKa, project number 1713074).

PY - 2012/8

Y1 - 2012/8

N2 - Leukaemia in neonates (infants <1 month) is rare, whereby neonatal acute myeloid leukaemia (AML) is more frequent than neonatal acute lymphoblastic leukaemia (ALL). High mortality rates are observed, though AML has a better prognosis than ALL. Neonatal leukaemia is typically presented with hepatosplenomegaly, leukaemia cutis and/or hyperleucocytosis. Congenital infections should be ruled out before diagnosis. Rearrangement of the . MLL gene is the most frequently occurring genetic aberration. Treatment includes intensive multi-agent chemotherapy, usually with age-related dose adjustments next to supportive care. Treatment intensification for ALL could be indicated in the future as the dismal prognosis is subject to high relapse rates in ALL.

AB - Leukaemia in neonates (infants <1 month) is rare, whereby neonatal acute myeloid leukaemia (AML) is more frequent than neonatal acute lymphoblastic leukaemia (ALL). High mortality rates are observed, though AML has a better prognosis than ALL. Neonatal leukaemia is typically presented with hepatosplenomegaly, leukaemia cutis and/or hyperleucocytosis. Congenital infections should be ruled out before diagnosis. Rearrangement of the . MLL gene is the most frequently occurring genetic aberration. Treatment includes intensive multi-agent chemotherapy, usually with age-related dose adjustments next to supportive care. Treatment intensification for ALL could be indicated in the future as the dismal prognosis is subject to high relapse rates in ALL.

KW - Acute lymphoblastic leukaemia

KW - Acute myeloid leukaemia

KW - Mixed lineage leukaemia

KW - Neonate

UR - https://www.scopus.com/pages/publications/84862200420

U2 - 10.1016/j.siny.2012.03.003

DO - 10.1016/j.siny.2012.03.003

M3 - Review article

C2 - 22510298

AN - SCOPUS:84862200420

SN - 1744-165X

VL - 17

SP - 192

EP - 195

JO - Seminars in Fetal and Neonatal Medicine

JF - Seminars in Fetal and Neonatal Medicine

IS - 4

ER -

Diagnosis and management of neonatal leukaemia

Abstract

Keywords

Access to Document

Fingerprint

Cite this